InfectRisk

Flu season in Norway

Current flu, COVID-19 and RSV activity in Norway, based on ECDC ERVISS weekly data from the Norwegian Institute of Public Health (FHI). Rescaled into a consultation-equivalent signal for a qualitative low / moderate / high classification.

Influenza: Low

Low

The source currently reports no meaningful activity (as of 16 Aug 2026).

Data window: Week 33 · Aug 10 – Aug 16 · Source: ECDC (weekly) · Source on seasonal break, next data from week 40

Get one free alert when the wave turns in Norway

We write exactly once: the moment the level goes up. No account, no newsletter. We store your address and the country, nothing else. Every mail has a one click unsubscribe. Privacy

View the last 8 weeks

In week 33 of 2026, Influenza activity in Norway is classified as low.

The source reports no meaningful activity across these weeks; a week-over-week percentage would be pure noise here.

The last 8 reported weeks

WeekRelativeLevelvs prior week
Week 33Low
Week 32Low
Week 31Low
Week 30Low
Week 29Low
Week 28Low
Week 27Low
Week 26Low

Across these weeks the source reports no meaningful activity, the values sit at the floor of its scale.

Is flu going around right now?

Know when it affects you.

This page shows your country. The app shows you.

  • Exact numbers and incidence rates, not just low, moderate, high
  • Your personal risk by age and region
  • A push alert when the wave tips in your region
  • 35 countries and a home-screen widget
Download on the

Current activity

12-week trend · Influenza · Relative development · ECDC ERVISS
Week 22Week 25Week 28Week 30Week 33
  • InfluenzaLow
    Trend: stable · Week 33
  • COVID-19Low
    Trend: rising · Week 33
  • RSVLow
    Trend: stable · Week 33

What this means

In week 33 of 2026, activity of influenza (seasonal flu) in Norway is low. The trend, derived from clinical surveillance, is stable.

Data, context and methodology

The current picture for Norway is built on the European Respiratory Virus Surveillance Summary (ERVISS), published weekly by the European Centre for Disease Prevention and Control (ECDC). the Norwegian Institute of Public Health (FHI) via its sentinel GP network and wastewater surveillance is the national public-health authority that feeds ERVISS with sentinel primary care and virology data.

ECDC ERVISS

ERVISS is ECDC's weekly pan-European surveillance summary for influenza, SARS-CoV-2 and RSV. National authorities, in Norway's case the Norwegian Institute of Public Health (FHI) via its sentinel GP network and wastewater surveillance, submit harmonised indicators every week, which ECDC publishes in a standardised dataset on Thursdays. Using ERVISS rather than each country's native portal ensures cross-country comparability.

ILI / ARI consultation rates and positivity

the Norwegian Institute of Public Health (FHI) via its sentinel GP network and wastewater surveillance operates a sentinel network of general practices that report weekly rates of patients consulting for influenza-like illness (ILI) or acute respiratory infection (ARI). A subset of patients is swabbed and tested by reference laboratories, producing pathogen-specific positivity rates for flu, SARS-CoV-2 and RSV.

Why this source

Combining consultation incidence with virological positivity yields a pathogen-specific weekly incidence signal (ILI × positivity / 100). This is the standard European methodology and provides a more robust view than either indicator alone: consultation rates capture illness burden, positivity confirms which pathogen is driving it.

Qualitative classification

The “low”, “moderate” and “high” categories follow seasonal reference values and epidemiological thresholds calibrated to match our classifications for other countries. The ILI × positivity / 100 product is scaled to comparable thresholds using a divisor of 3, which aligns European sentinel peaks with the consultation-equivalent scale used elsewhere. Data refreshes weekly when ECDC publishes the latest ERVISS update, typically on Thursdays.

Source and seasonal pattern by pathogen

Influenza
The classification is based on the ECDC ERVISS weekly reports, drawing on data from the Norwegian Institute of Public Health (FHI) via its sentinel GP network and wastewater surveillance. Seasonally, infection waves in Norway typically peak between January and March; activity is usually markedly lower during the summer months.
COVID-19
The classification is based on the ECDC ERVISS weekly reports, drawing on COVID-19 surveillance data from the Norwegian Institute of Public Health (FHI) via its sentinel GP network and wastewater surveillance. Seasonally, infection waves in Norway typically peak during winter, with occasional summer waves driven by new variants; activity is usually markedly lower in late spring between waves.
RSV
The classification is based on the ECDC ERVISS weekly reports, drawing on RSV surveillance data from the Norwegian Institute of Public Health (FHI) via its sentinel GP network and wastewater surveillance. Seasonally, infection waves in Norway typically peak between December and February; activity is usually markedly lower in spring and summer.

Frequently asked questions

When is flu season in Norway?

Norwegian flu activity usually starts rising in late December, peaks between January and March, and tails off by April. The exact onset and peak shift year to year with the dominant subtypes and residual immunity. FHI, the Norwegian Institute of Public Health (Folkehelseinstituttet), publishes weekly influenza updates through its sentinel GP network and national reference laboratory. Nordic climates concentrate indoor contact in the darkest months, which shapes the winter respiratory curve.

How does FHI classify flu severity?

FHI describes influenza activity in qualitative bands (low, moderate, high, and very high) based on sentinel consultations, laboratory positivity, and hospital indicators. These classifications appear in the weekly respiratory-virus bulletin and are also reported to ECDC for the European Respiratory Virus Surveillance Summary (ERVISS). The qualitative framing helps clinicians and the public interpret whether the season is ordinary, elevated, or exceptional.

How is flu surveillance organised in Norway?

Norway's influenza surveillance combines a sentinel network of general practitioners, laboratory testing coordinated by FHI, hospital notifications of severe cases, and wastewater monitoring at selected treatment plants. Wastewater adds an early signal independent of test-seeking behaviour and complements the clinical indicators. Weekly bulletins summarise the full picture and feed ECDC ERVISS, which places Norway's trajectory alongside Sweden, Finland, and the rest of the EU/EEA.

Is the flu vaccine free in Norway?

Norway offers seasonal influenza vaccination at a reduced, subsidised cost for defined risk groups (older adults from 65 and up, pregnant women after the first trimester, people with chronic illnesses, and healthcare workers) delivered through GPs, pharmacies, and municipal services. Some municipalities and employer-paid schemes cover the full cost for certain groups. FHI reports vaccine-uptake estimates alongside the weekly surveillance bulletin.

How does Norway compare to its Nordic neighbours?

Because Norway reports into ECDC ERVISS with harmonised indicators, its weekly flu classification is directly comparable with Sweden, Denmark, Finland, and Iceland. Nordic countries typically see broadly similar peak windows between January and March. Lead–lag patterns of a few weeks are common and are visible in ECDC's side-by-side dashboards.

More situation reports

ECDC ERVISSECDC DataUpdated: Aug 31, 2026, 11:10
Published by Dominik Martin · Software engineer and data aggregator· Methodology last reviewed: 07 May 2026· Methodology version 1.2

Data last refreshed: Aug 31, 2026, 11:10. Update cadence: weekly.

This page is not medical advice and does not replace consultation with a healthcare professional. For specific symptoms, please contact a medical professional.

About this page

Published by Renderei Martin GmbH, Berlin. No commercial interest in individual health recommendations. The app is optionally monetised via a freemium subscription.

Content is based exclusively on the linked official surveillance publications. Medical statements are curated against the guidance of RKI, ECDC and WHO.

Methodology enquiries: press@infectrisk.com

About this site and its author